SCHEMBL4267067

SCHEMBL4267067

COc1ccc(/C=C/S(=O)(=O)NC(=O)c2ccc(F)cc2C(F)(F)F)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 3/20 0.42
RAB9A P51151 2/20 0.42
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
POLB P06746 2/20 0.41
PADI4 Q9UM07 1/20 0.40
MEN1 O00255 2/20 0.39
SLC22A12 Q96S37 1/20 0.39
MAPK10 P53779 2/20 0.39
SCN9A Q15858 1/20 0.39
RPS6KB1 P23443 1/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4267072 1.00 NPC1 (0.42) NPC1SMN1; SMN2LMNARAB9AKMT2A
SCHEMBL4253752 0.90 FLT1 (0.44) NPC1SMN1; SMN2LMNARAB9AKMT2A
SCHEMBL4258496 0.86 SMN1; SMN2 (0.43) NPC1SMN1; SMN2LMNARAB9AKMT2A
SCHEMBL4258490 0.86 SMN1; SMN2 (0.43) NPC1SMN1; SMN2LMNARAB9AKMT2A
SCHEMBL4261164 0.86 NPC1 (0.43) NPC1SMN1; SMN2LMNARAB9AKMT2A
SCHEMBL4261166 0.86 NPC1 (0.43) NPC1SMN1; SMN2LMNARAB9AKMT2A
SCHEMBL4264129 0.83 MAPK10 (0.45) NPC1SMN1; SMN2LMNARAB9AKMT2A
SCHEMBL5414593 0.80 NFE2L2 (0.45) NPC1SMN1; SMN2RAB9AKMT2AMAPT
SCHEMBL5414587 0.80 NFE2L2 (0.45) NPC1SMN1; SMN2RAB9AKMT2AMAPT
SCHEMBL5418925 0.80 PTGES2 (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 NPC1 254/4885SMN1; SMN2 4219/4885LMNA 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.